{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:50:25Z","timestamp":1791395425529,"version":"4.3.3"},"reference-count":132,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":778,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s13311-021-01122-6","type":"journal-article","created":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T07:46:32Z","timestamp":1633419992000},"page":"1548-1563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Precision Therapy for Epilepsy Related to Brain Malformations"],"prefix":"10.1016","volume":"18","author":[{"given":"Alissa M.","family":"D'Gama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7350-5136","authenticated-orcid":false,"given":"Annapurna","family":"Poduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-021-01122-6_bib1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1055\/s-2007-973750","article-title":"A classification scheme for malformations of cortical development","volume":"27","author":"Barkovich","year":"1996","journal-title":"Neuropediatrics."},{"key":"10.1007\/s13311-021-01122-6_bib2","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/brain\/aws019","article-title":"A developmental and genetic classification for malformations of cortical development: update 2012","volume":"135","author":"Barkovich","year":"2012","journal-title":"Brain."},{"key":"10.1007\/s13311-021-01122-6_bib3","doi-asserted-by":"crossref","unstructured":"Barkovich AJ, Dobyns WB, Guerrini R. Malformations of cortical development and epilepsy. Cold Spring Harb Perspect Med. 2015;5:a022392.","DOI":"10.1101\/cshperspect.a022392"},{"key":"10.1007\/s13311-021-01122-6_bib4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1684\/epd.2015.0736","article-title":"Incidence, prevalence and aetiology of seizures and epilepsy in children","volume":"17","author":"Camfield","year":"2015","journal-title":"Epileptic Disord."},{"key":"10.1007\/s13311-021-01122-6_bib5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.seizure.2019.12.020","article-title":"Incidence of early-onset epilepsy: A prospective population-based study","volume":"75","author":"Hunter","year":"2020","journal-title":"Seizure."},{"key":"10.1007\/s13311-021-01122-6_bib6","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.seizure.2012.03.009","article-title":"Malformations of cortical development and epilepsy in adult patients","volume":"21","author":"Papayannis","year":"2012","journal-title":"Seizure."},{"key":"10.1007\/s13311-021-01122-6_bib7","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1212\/WNL.53.4.715","article-title":"Clinical and imaging features of cortical malformations in childhood","volume":"53","author":"Leventer","year":"1999","journal-title":"Neurology."},{"issue":"Suppl 6","key":"10.1007\/s13311-021-01122-6_bib8","first-page":"S44","article-title":"Magnetic resonance imaging in developmental disorders of the cerebral cortex","volume":"35","author":"Kuzniecky","year":"1994","journal-title":"Epilepsia."},{"key":"10.1007\/s13311-021-01122-6_bib9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1684\/epd.2018.0959","article-title":"Epilepsy surgery for patients with genetic refractory epilepsy: a systematic review","volume":"20","author":"Stevelink","year":"2018","journal-title":"Epileptic Disord."},{"key":"10.1007\/s13311-021-01122-6_bib10","doi-asserted-by":"crossref","unstructured":"Harvey AS, Cross JH, Shinnar S, Mathern GW, Taskforce IPESS. Defining the spectrum of international practice in pediatric epilepsy surgery patients. Epilepsia. 2008;49:146\u201355.","DOI":"10.1111\/j.1528-1167.2007.01421.x"},{"key":"10.1007\/s13311-021-01122-6_bib11","doi-asserted-by":"crossref","unstructured":"West S, Nevitt SJ, Cotton J, et al. Surgery for epilepsy. Cochrane Database Syst Rev. 2019;6:CD010541.","DOI":"10.1002\/14651858.CD012065.pub3"},{"key":"10.1007\/s13311-021-01122-6_bib12","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1056\/NEJMoa1703784","article-title":"Histopathological Findings in Brain Tissue Obtained during Epilepsy Surgery","volume":"377","author":"Blumcke","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1007\/s13311-021-01122-6_bib13","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3389\/fnins.2019.00250","article-title":"Why Malformations of Cortical Development Cause Epilepsy","volume":"13","author":"Represa","year":"2019","journal-title":"Front Neurosci."},{"key":"10.1007\/s13311-021-01122-6_bib14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev-pathmechdis-012418-012927","article-title":"Malformations of Cerebral Cortex Development: Molecules and Mechanisms","volume":"14","author":"Juric-Sekhar","year":"2019","journal-title":"Annu Rev Pathol."},{"key":"10.1007\/s13311-021-01122-6_bib15","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/joa.12956","article-title":"New insights into a spectrum of developmental malformations related to mTOR dysregulations: challenges and perspectives","volume":"235","author":"Muhlebner","year":"2019","journal-title":"J Anat."},{"key":"10.1007\/s13311-021-01122-6_bib16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.neuron.2012.03.010","article-title":"Somatic activation of AKT3 causes hemispheric developmental brain malformations","volume":"74","author":"Poduri","year":"2012","journal-title":"Neuron."},{"key":"10.1007\/s13311-021-01122-6_bib17","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ana.24126","article-title":"Mutations in mammalian target of rapamycin regulator DEPDC5 cause focal epilepsy with brain malformations","volume":"75","author":"Scheffer","year":"2014","journal-title":"Ann Neurol."},{"key":"10.1007\/s13311-021-01122-6_bib18","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/ng.2329","article-title":"De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly","volume":"44","author":"Lee","year":"2012","journal-title":"Nat Genet."},{"key":"10.1007\/s13311-021-01122-6_bib19","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/ng.2331","article-title":"De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes","volume":"44","author":"Riviere","year":"2012","journal-title":"Nat Genet."},{"key":"10.1007\/s13311-021-01122-6_bib20","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1126\/science.277.5327.805","article-title":"Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34","volume":"277","author":"van Slegtenhorst","year":"1997","journal-title":"Science."},{"key":"10.1007\/s13311-021-01122-6_bib21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1749-6632.1991.tb37754.x","article-title":"Epidemiology of tuberous sclerosis","volume":"615","author":"Osborne","year":"1991","journal-title":"Ann N Y Acad Sci."},{"issue":"Suppl","key":"10.1007\/s13311-021-01122-6_bib22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0387-7604(94)00130-8","article-title":"History of the tuberous sclerosis complex","volume":"17","author":"Gomez","year":"1995","journal-title":"Brain Dev."},{"key":"10.1007\/s13311-021-01122-6_bib23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pediatrneurol.2014.10.004","article-title":"Tuberous sclerosis associated neuropsychiatric disorders (TAND) and the TAND Checklist","volume":"52","author":"de Vries","year":"2015","journal-title":"Pediatr Neurol."},{"key":"10.1007\/s13311-021-01122-6_bib24","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1017\/S0033291702007092","article-title":"Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex","volume":"33","author":"Joinson","year":"2003","journal-title":"Psychol Med."},{"key":"10.1007\/s13311-021-01122-6_bib25","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S2215-0366(15)00376-4","article-title":"Prevalence of autism spectrum disorder phenomenology in genetic disorders: a systematic review and meta-analysis","volume":"2","author":"Richards","year":"2015","journal-title":"Lancet Psychiatry."},{"key":"10.1007\/s13311-021-01122-6_bib26","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1528-1167.2009.02474.x","article-title":"The natural history of epilepsy in tuberous sclerosis complex","volume":"51","author":"Chu-Shore","year":"2010","journal-title":"Epilepsia."},{"key":"10.1007\/s13311-021-01122-6_bib27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.pediatrneurol.2019.12.016","article-title":"Epilepsy and Neurodevelopmental Comorbidities in Tuberous Sclerosis Complex: A Natural History Study","volume":"106","author":"Gupta","year":"2020","journal-title":"Pediatr Neurol."},{"key":"10.1007\/s13311-021-01122-6_bib28","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1177\/08830738040190090801","article-title":"Managing epilepsy in tuberous sclerosis complex","volume":"19","author":"Thiele","year":"2004","journal-title":"J Child Neurol."},{"key":"10.1007\/s13311-021-01122-6_bib29","doi-asserted-by":"crossref","unstructured":"Davis PE, Filip-Dhima R, Sideridis G, et al. Presentation and Diagnosis of Tuberous Sclerosis Complex in Infants. Pediatrics. 2017;140.","DOI":"10.1542\/peds.2016-4040"},{"key":"10.1007\/s13311-021-01122-6_bib30","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1474-4422(15)00069-1","article-title":"Neurological and neuropsychiatric aspects of tuberous sclerosis complex","volume":"14","author":"Curatolo","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1007\/s13311-021-01122-6_bib31","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMra055323","article-title":"The tuberous sclerosis complex","volume":"355","author":"Crino","year":"2006","journal-title":"N Engl J Med."},{"key":"10.1007\/s13311-021-01122-6_bib32","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.eplepsyres.2013.02.016","article-title":"Predictors of seizure freedom after surgical management of tuberous sclerosis complex: a systematic review and meta-analysis","volume":"105","author":"Zhang","year":"2013","journal-title":"Epilepsy Res."},{"key":"10.1007\/s13311-021-01122-6_bib33","doi-asserted-by":"crossref","unstructured":"European Chromosome 16 Tuberous Sclerosis C. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75:1305\u201315.","DOI":"10.1016\/0092-8674(93)90618-Z"},{"key":"10.1007\/s13311-021-01122-6_bib34","unstructured":"Northrup H, Koenig MK, Pearson DA, Au KS. Tuberous Sclerosis Complex. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, et al., editors. GeneReviews((R)). Seattle (WA)1993."},{"key":"10.1007\/s13311-021-01122-6_bib35","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/s41436-020-0823-4","article-title":"TSC2 pathogenic variants are predictive of severe clinical manifestations in TSC infants: results of the EPISTOP study","volume":"22","author":"Ogorek","year":"2020","journal-title":"Genet Med."},{"key":"10.1007\/s13311-021-01122-6_bib36","doi-asserted-by":"crossref","unstructured":"Tyburczy ME, Dies KA, Glass J, et al. Mosaic and Intronic Mutations in TSC1\/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing. PLoS Genet. 2015;11:e1005637.","DOI":"10.1371\/journal.pgen.1005637"},{"key":"10.1007\/s13311-021-01122-6_bib37","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1073\/pnas.68.4.820","article-title":"Mutation and cancer: statistical study of retinoblastoma","volume":"68","author":"Knudson","year":"1971","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1007\/s13311-021-01122-6_bib38","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1212\/WNL.0b013e3181e04325","article-title":"Biallelic TSC gene inactivation in tuberous sclerosis complex","volume":"74","author":"Crino","year":"2010","journal-title":"Neurology."},{"key":"10.1007\/s13311-021-01122-6_bib39","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/j.1750-3639.2010.00416.x","article-title":"Analysis of TSC cortical tubers by deep sequencing of TSC1, TSC2 and KRAS demonstrates that small second-hit mutations in these genes are rare events","volume":"20","author":"Qin","year":"2010","journal-title":"Brain Pathol."},{"key":"10.1007\/s13311-021-01122-6_bib40","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1093\/hmg\/ddu597","article-title":"A shower of second hit events as the cause of multifocal renal cell carcinoma in tuberous sclerosis complex","volume":"24","author":"Tyburczy","year":"2015","journal-title":"Hum Mol Genet."},{"key":"10.1007\/s13311-021-01122-6_bib41","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1016\/j.celrep.2017.11.106","article-title":"Somatic Mutations Activating the mTOR Pathway in Dorsal Telencephalic Progenitors Cause a Continuum of Cortical Dysplasias","volume":"21","author":"D'Gama","year":"2017","journal-title":"Cell Rep."},{"key":"10.1007\/s13311-021-01122-6_bib42","doi-asserted-by":"crossref","unstructured":"Condon KJ, Sabatini DM. Nutrient regulation of mTORC1 at a glance. J Cell Sci. 2019;132.","DOI":"10.1242\/jcs.222570"},{"key":"10.1007\/s13311-021-01122-6_bib43","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/ncb839","article-title":"TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling","volume":"4","author":"Inoki","year":"2002","journal-title":"Nat Cell Biol."},{"key":"10.1007\/s13311-021-01122-6_bib44","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cell.2017.03.035","article-title":"mTOR Signaling in Growth, Metabolism, and Disease","volume":"169","author":"Saxton","year":"2017","journal-title":"Cell."},{"key":"10.1007\/s13311-021-01122-6_bib45","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.phrs.2016.03.039","article-title":"mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis","volume":"107","author":"Citraro","year":"2016","journal-title":"Pharmacol Res."},{"key":"10.1007\/s13311-021-01122-6_bib46","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.molcel.2012.06.009","article-title":"TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1","volume":"47","author":"Dibble","year":"2012","journal-title":"Mol Cell."},{"key":"10.1007\/s13311-021-01122-6_bib47","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1101\/gad.1110003","article-title":"Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling","volume":"17","author":"Inoki","year":"2003","journal-title":"Genes Dev."},{"key":"10.1007\/s13311-021-01122-6_bib48","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.cub.2005.02.053","article-title":"Rheb binds and regulates the mTOR kinase","volume":"15","author":"Long","year":"2005","journal-title":"Curr Biol."},{"key":"10.1007\/s13311-021-01122-6_bib49","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ng1494","article-title":"Dysregulation of the TSC-mTOR pathway in human disease","volume":"37","author":"Inoki","year":"2005","journal-title":"Nat Genet."},{"key":"10.1007\/s13311-021-01122-6_bib50","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s13311-013-0251-0","article-title":"Epilepsy related to developmental tumors and malformations of cortical development","volume":"11","author":"Aronica","year":"2014","journal-title":"Neurotherapeutics."},{"key":"10.1007\/s13311-021-01122-6_bib51","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/14728222.2017.1316715","article-title":"DEPDC5 as a potential therapeutic target for epilepsy","volume":"21","author":"Myers","year":"2017","journal-title":"Expert Opin Ther Targets."},{"key":"10.1007\/s13311-021-01122-6_bib52","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.21331","article-title":"Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex","volume":"63","author":"Zeng","year":"2008","journal-title":"Ann Neurol."},{"key":"10.1007\/s13311-021-01122-6_bib53","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1523\/JNEUROSCI.0955-08.2008","article-title":"Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function","volume":"28","author":"Meikle","year":"2008","journal-title":"J Neurosci."},{"key":"10.1007\/s13311-021-01122-6_bib54","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/hmg\/ddq491","article-title":"Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex","volume":"20","author":"Zeng","year":"2011","journal-title":"Hum Mol Genet."},{"key":"10.1007\/s13311-021-01122-6_bib55","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ana.20784","article-title":"Rapamycin causes regression of astrocytomas in tuberous sclerosis complex","volume":"59","author":"Franz","year":"2006","journal-title":"Ann Neurol."},{"key":"10.1007\/s13311-021-01122-6_bib56","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N Engl J Med."},{"key":"10.1007\/s13311-021-01122-6_bib57","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1212\/WNL.0b013e3182815428","article-title":"Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma","volume":"80","author":"Krueger","year":"2013","journal-title":"Neurology."},{"key":"10.1007\/s13311-021-01122-6_bib58","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/ana.24523","article-title":"Everolimus for subependymal giant cell astrocytoma: 5-year final analysis","volume":"78","author":"Franz","year":"2015","journal-title":"Ann Neurol."},{"key":"10.1007\/s13311-021-01122-6_bib59","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet."},{"key":"10.1007\/s13311-021-01122-6_bib60","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S1470-2045(14)70489-9","article-title":"Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study","volume":"15","author":"Franz","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1007\/s13311-021-01122-6_bib61","doi-asserted-by":"crossref","unstructured":"Franz DN, Belousova E, Sparagana S, et al. Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study. PLoS One. 2016;11:e0158476.","DOI":"10.1371\/journal.pone.0158476"},{"key":"10.1007\/s13311-021-01122-6_bib62","doi-asserted-by":"crossref","unstructured":"Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study. PLoS One. 2017;12:e0180939.","DOI":"10.1371\/journal.pone.0180939"},{"key":"10.1007\/s13311-021-01122-6_bib63","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ndt\/gfv249","article-title":"Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial","volume":"31","author":"Bissler","year":"2016","journal-title":"Nephrol Dial Transplant."},{"key":"10.1007\/s13311-021-01122-6_bib64","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","article-title":"Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"381","author":"Bissler","year":"2013","journal-title":"Lancet."},{"key":"10.1007\/s13311-021-01122-6_bib65","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1177\/0883073808324535","article-title":"Rapamycin reduces seizure frequency in tuberous sclerosis complex","volume":"24","author":"Muncy","year":"2009","journal-title":"J Child Neurol."},{"key":"10.1007\/s13311-021-01122-6_bib66","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/ana.23960","article-title":"Everolimus treatment of refractory epilepsy in tuberous sclerosis complex","volume":"74","author":"Krueger","year":"2013","journal-title":"Ann Neurol."},{"key":"10.1007\/s13311-021-01122-6_bib67","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1212\/WNL.0000000000003400","article-title":"Long-term treatment of epilepsy with everolimus in tuberous sclerosis","volume":"87","author":"Krueger","year":"2016","journal-title":"Neurology."},{"key":"10.1007\/s13311-021-01122-6_bib68","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"French","year":"2016","journal-title":"Lancet."},{"key":"10.1007\/s13311-021-01122-6_bib69","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1212\/CPJ.0000000000000514","article-title":"Everolimus for treatment-refractory seizures in TSC: Extension of a randomized controlled trial","volume":"8","author":"Franz","year":"2018","journal-title":"Neurol Clin Pract."},{"key":"10.1007\/s13311-021-01122-6_bib70","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S2352-4642(18)30099-3","article-title":"Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial","volume":"2","author":"Curatolo","year":"2018","journal-title":"Lancet Child Adolesc Health."},{"key":"10.1007\/s13311-021-01122-6_bib71","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.ejpn.2018.06.007","article-title":"Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience","volume":"22","author":"Krueger","year":"2018","journal-title":"Eur J Paediatr Neurol."},{"key":"10.1007\/s13311-021-01122-6_bib72","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ejpn.2013.06.002","article-title":"Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option?","volume":"17","author":"Wiegand","year":"2013","journal-title":"Eur J Paediatr Neurol."},{"key":"10.1007\/s13311-021-01122-6_bib73","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jpeds.2013.12.053","article-title":"Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex","volume":"164","author":"Cardamone","year":"2014","journal-title":"J Pediatr."},{"key":"10.1007\/s13311-021-01122-6_bib74","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1212\/WNL.0000000000003077","article-title":"Sirolimus for epilepsy in children with tuberous sclerosis complex: A randomized controlled trial","volume":"87","author":"Overwater","year":"2016","journal-title":"Neurology."},{"key":"10.1007\/s13311-021-01122-6_bib75","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13023-016-0530-z","article-title":"Efficacy and safety of Everolimus in children with TSC - associated epilepsy - Pilot data from an open single-center prospective study","volume":"11","author":"Samueli","year":"2016","journal-title":"Orphanet J Rare Dis."},{"key":"10.1007\/s13311-021-01122-6_bib76","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.seizure.2020.03.018","article-title":"Sirolimus improves seizure control in pediatric patients with tuberous sclerosis: A prospective cohort study","volume":"79","author":"He","year":"2020","journal-title":"Seizure."},{"key":"10.1007\/s13311-021-01122-6_bib77","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ejpn.2018.05.006","article-title":"Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations","volume":"22","author":"Curatolo","year":"2018","journal-title":"Eur J Paediatr Neurol."},{"key":"10.1007\/s13311-021-01122-6_bib78","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40272-019-00376-0","article-title":"Update on Drug Management of Refractory Epilepsy in Tuberous Sclerosis Complex","volume":"22","author":"van der Poest","year":"2020","journal-title":"Paediatr Drugs."},{"key":"10.1007\/s13311-021-01122-6_bib79","doi-asserted-by":"crossref","unstructured":"Zhang B, McDaniel SS, Rensing NR, Wong M. Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex. PLoS One. 2013;8:e57445.","DOI":"10.1371\/journal.pone.0057445"},{"key":"10.1007\/s13311-021-01122-6_bib80","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.25956","article-title":"Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial","volume":"89","author":"Kotulska","year":"2021","journal-title":"Ann Neurol."},{"key":"10.1007\/s13311-021-01122-6_bib81","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1136\/jnnp.34.4.369","article-title":"Focal dysplasia of the cerebral cortex in epilepsy","volume":"34","author":"Taylor","year":"1971","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1007\/s13311-021-01122-6_bib82","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1528-1167.2010.02777.x","article-title":"The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission","volume":"52","author":"Blumcke","year":"2011","journal-title":"Epilepsia."},{"key":"10.1007\/s13311-021-01122-6_bib83","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/095952873501900120","article-title":"On Hypertrophy and Atrophy of the Brain","volume":"19","author":"Sims","year":"1835","journal-title":"Med Chir Trans."},{"key":"10.1007\/s13311-021-01122-6_bib84","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1600-0404.2005.00555.x","article-title":"Focal cortical dysplasia: prevalence, clinical presentation and epilepsy in children and adults","volume":"113","author":"Bast","year":"2006","journal-title":"Acta Neurol Scand."},{"key":"10.1007\/s13311-021-01122-6_bib85","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s00381-006-0149-9","article-title":"Hemimegalencephaly: clinical implications and surgical treatment","volume":"22","author":"Di Rocco","year":"2006","journal-title":"Childs Nerv Syst."},{"key":"10.1007\/s13311-021-01122-6_bib86","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.eplepsyres.2017.03.001","article-title":"Epilepsy prevalence and severity predictors in MRI-identified focal cortical dysplasia","volume":"132","author":"Maynard","year":"2017","journal-title":"Epilepsy Res."},{"key":"10.1007\/s13311-021-01122-6_bib87","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.pediatrneurol.2012.12.024","article-title":"Focal cortical dysplasia","volume":"49","author":"Gaitanis","year":"2013","journal-title":"Pediatr Neurol."},{"key":"10.1007\/s13311-021-01122-6_bib88","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/08830738050200041201","article-title":"Clinical aspects of hemimegalencephaly by means of a nationwide survey","volume":"20","author":"Sasaki","year":"2005","journal-title":"J Child Neurol."},{"key":"10.1007\/s13311-021-01122-6_bib89","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/ana.20211","article-title":"mTOR cascade activation distinguishes tubers from focal cortical dysplasia","volume":"56","author":"Baybis","year":"2004","journal-title":"Ann Neurol."},{"key":"10.1007\/s13311-021-01122-6_bib90","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/ana.20234","article-title":"Insulin signaling pathways in cortical dysplasia and TSC-tubers: tissue microarray analysis","volume":"56","author":"Miyata","year":"2004","journal-title":"Ann Neurol."},{"key":"10.1007\/s13311-021-01122-6_bib91","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/ana.20949","article-title":"Activation of mammalian target of rapamycin in cytomegalic neurons of human cortical dysplasia","volume":"60","author":"Ljungberg","year":"2006","journal-title":"Ann Neurol."},{"key":"10.1007\/s13311-021-01122-6_bib92","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nm.3824","article-title":"Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy","volume":"21","author":"Lim","year":"2015","journal-title":"Nat Med."},{"key":"10.1007\/s13311-021-01122-6_bib93","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/brain\/awv045","article-title":"PI3K\/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia","volume":"138","author":"Jansen","year":"2015","journal-title":"Brain."},{"key":"10.1007\/s13311-021-01122-6_bib94","doi-asserted-by":"crossref","unstructured":"Salinas V, Vega P, Piccirilli MV, et al. Identification of a somatic mutation in the RHEB gene through high depth and ultra-high depth next generation sequencing in a patient with Hemimegalencephaly and drug resistant Epilepsy. Eur J Med Genet. 2019;62:103571.","DOI":"10.1016\/j.ejmg.2018.11.005"},{"key":"10.1007\/s13311-021-01122-6_bib95","first-page":"1","article-title":"A brain somatic RHEB doublet mutation causes focal cortical dysplasia type II","volume":"51","author":"Zhao","year":"2019","journal-title":"Exp Mol Med."},{"key":"10.1007\/s13311-021-01122-6_bib96","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/ana.24368","article-title":"Familial focal epilepsy with focal cortical dysplasia due to DEPDC5 mutations","volume":"77","author":"Baulac","year":"2015","journal-title":"Ann Neurol."},{"key":"10.1007\/s13311-021-01122-6_bib97","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/ana.24357","article-title":"Mammalian target of rapamycin pathway mutations cause hemimegalencephaly and focal cortical dysplasia","volume":"77","author":"D'Gama","year":"2015","journal-title":"Ann Neurol."},{"key":"10.1007\/s13311-021-01122-6_bib98","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ajhg.2017.01.030","article-title":"Somatic Mutations in TSC1 and TSC2 Cause Focal Cortical Dysplasia","volume":"100","author":"Lim","year":"2017","journal-title":"Am J Hum Genet."},{"key":"10.1007\/s13311-021-01122-6_bib99","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00401-006-0128-y","article-title":"Activation of Akt independent of PTEN and CTMP tumor-suppressor gene mutations in epilepsy-associated Taylor-type focal cortical dysplasias","volume":"112","author":"Schick","year":"2006","journal-title":"Acta Neuropathol."},{"key":"10.1007\/s13311-021-01122-6_bib100","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/ana.24502","article-title":"Familial cortical dysplasia caused by mutation in the mammalian target of rapamycin regulator NPRL3","volume":"79","author":"Sim","year":"2016","journal-title":"Ann Neurol."},{"key":"10.1007\/s13311-021-01122-6_bib101","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/epi.13391","article-title":"Involvement of GATOR complex genes in familial focal epilepsies and focal cortical dysplasia","volume":"57","author":"Weckhuysen","year":"2016","journal-title":"Epilepsia."},{"key":"10.1007\/s13311-021-01122-6_bib102","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/acn3.50815","article-title":"Second-hit DEPDC5 mutation is limited to dysmorphic neurons in cortical dysplasia type IIA","volume":"6","author":"Lee","year":"2019","journal-title":"Ann Clin Transl Neurol."},{"key":"10.1007\/s13311-021-01122-6_bib103","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/nm.3982","article-title":"An AKT3-FOXG1-reelin network underlies defective migration in human focal malformations of cortical development","volume":"21","author":"Baek","year":"2015","journal-title":"Nat Med."},{"key":"10.1007\/s13311-021-01122-6_bib104","doi-asserted-by":"crossref","unstructured":"Roy A, Skibo J, Kalume F, et al. Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy. Elife. 2015;4.","DOI":"10.7554\/eLife.12703"},{"key":"10.1007\/s13311-021-01122-6_bib105","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1242\/dmm.002386","article-title":"Rapamycin suppresses seizures and neuronal hypertrophy in a mouse model of cortical dysplasia","volume":"2","author":"Ljungberg","year":"2009","journal-title":"Dis Model Mech."},{"key":"10.1007\/s13311-021-01122-6_bib106","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/epi.12946","article-title":"mTOR inhibition suppresses established epilepsy in a mouse model of cortical dysplasia","volume":"56","author":"Nguyen","year":"2015","journal-title":"Epilepsia."},{"key":"10.1007\/s13311-021-01122-6_bib107","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1523\/JNEUROSCI.5685-08.2009","article-title":"Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice","volume":"29","author":"Zhou","year":"2009","journal-title":"J Neurosci."},{"key":"10.1007\/s13311-021-01122-6_bib108","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.nbd.2016.02.010","article-title":"Depdc5 knockout rat: A novel model of mTORopathy","volume":"89","author":"Marsan","year":"2016","journal-title":"Neurobiol Dis."},{"key":"10.1007\/s13311-021-01122-6_bib109","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1172\/JCI99384","article-title":"Second-hit mosaic mutation in mTORC1 repressor DEPDC5 causes focal cortical dysplasia-associated epilepsy","volume":"128","author":"Ribierre","year":"2018","journal-title":"J Clin Invest."},{"key":"10.1007\/s13311-021-01122-6_bib110","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.nbd.2017.12.010","article-title":"A mouse model of DEPDC5-related epilepsy: Neuronal loss of Depdc5 causes dysplastic and ectopic neurons, increased mTOR signaling, and seizure susceptibility","volume":"111","author":"Yuskaitis","year":"2018","journal-title":"Neurobiol Dis."},{"key":"10.1007\/s13311-021-01122-6_bib111","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1093\/hmg\/ddz123","article-title":"Chronic mTORC1 inhibition rescues behavioral and biochemical deficits resulting from neuronal Depdc5 loss in mice","volume":"28","author":"Yuskaitis","year":"2019","journal-title":"Hum Mol Genet."},{"key":"10.1007\/s13311-021-01122-6_bib112","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/0883073818813238","article-title":"mTOR Inhibitors as a New Therapeutic Strategy in Treatment Resistant Epilepsy in Hemimegalencephaly: A Case Report","volume":"34","author":"Xu","year":"2019","journal-title":"J Child Neurol."},{"key":"10.1007\/s13311-021-01122-6_bib113","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejpn.2017.07.018","article-title":"Dramatic relapse of seizures after everolimus withdrawal","volume":"22","author":"Mingarelli","year":"2018","journal-title":"Eur J Paediatr Neurol."},{"key":"10.1007\/s13311-021-01122-6_bib114","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13023-017-0581-9","article-title":"Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide","volume":"12","author":"Davies","year":"2017","journal-title":"Orphanet J Rare Dis."},{"key":"10.1007\/s13311-021-01122-6_bib115","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1111\/epi.16370","article-title":"GATORopathies: The role of amino acid regulatory gene mutations in epilepsy and cortical malformations","volume":"60","author":"Iffland","year":"2019","journal-title":"Epilepsia."},{"key":"10.1007\/s13311-021-01122-6_bib116","doi-asserted-by":"crossref","unstructured":"Hillmann P, Fabbro D. PI3K\/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases. Int J Mol Sci. 2019;20.","DOI":"10.3390\/ijms20225792"},{"key":"10.1007\/s13311-021-01122-6_bib117","doi-asserted-by":"crossref","unstructured":"Jesus-Ribeiro J, Pires LM, Melo JD, et al. Genomic and Epigenetic Advances in Focal Cortical Dysplasia Types I and II: A Scoping Review. Front Neurosci. 2020;14:580357.","DOI":"10.3389\/fnins.2020.580357"},{"key":"10.1007\/s13311-021-01122-6_bib118","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/ana.25243","article-title":"Somatic SLC35A2 variants in the brain are associated with intractable neocortical epilepsy","volume":"83","author":"Winawer","year":"2018","journal-title":"Ann Neurol."},{"key":"10.1007\/s13311-021-01122-6_bib119","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00401-019-02061-5","article-title":"Dissecting the genetic basis of focal cortical dysplasia: a large cohort study","volume":"138","author":"Baldassari","year":"2019","journal-title":"Acta Neuropathol."},{"key":"10.1007\/s13311-021-01122-6_bib120","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40478-020-01085-3","article-title":"Frequent SLC35A2 brain mosaicism in mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE)","volume":"9","author":"Bonduelle","year":"2021","journal-title":"Acta Neuropathol Commun."},{"key":"10.1007\/s13311-021-01122-6_bib121","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/bpa.12347","article-title":"Mild Malformation of Cortical Development with Oligodendroglial Hyperplasia in Frontal Lobe Epilepsy: A New Clinico-Pathological Entity","volume":"27","author":"Schurr","year":"2017","journal-title":"Brain Pathol."},{"key":"10.1007\/s13311-021-01122-6_bib122","doi-asserted-by":"crossref","unstructured":"Sim NS, Seo Y, Lim JS, et al. Brain somatic mutations in SLC35A2 cause intractable epilepsy with aberrant N-glycosylation. Neurol Genet. 2018;4:e294.","DOI":"10.1212\/NXG.0000000000000294"},{"key":"10.1007\/s13311-021-01122-6_bib123","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s10545-015-9828-6","article-title":"A new case of UDP-galactose transporter deficiency (SLC35A2-CDG): molecular basis, clinical phenotype, and therapeutic approach","volume":"38","author":"Dorre","year":"2015","journal-title":"J Inherit Metab Dis."},{"key":"10.1007\/s13311-021-01122-6_bib124","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3389\/fneur.2019.00434","article-title":"Diagnostic Yield and Treatment Impact of Targeted Exome Sequencing in Early-Onset Epilepsy","volume":"10","author":"Demos","year":"2019","journal-title":"Front Neurol."},{"key":"10.1007\/s13311-021-01122-6_bib125","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1172\/JCI41592","article-title":"STRADalpha deficiency results in aberrant mTORC1 signaling during corticogenesis in humans and mice","volume":"120","author":"Orlova","year":"2010","journal-title":"J Clin Invest."},{"key":"10.1007\/s13311-021-01122-6_bib126","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1093\/brain\/awm100","article-title":"Polyhydramnios, megalencephaly and symptomatic epilepsy caused by a homozygous 7-kilobase deletion in LYK5","volume":"130","author":"Puffenberger","year":"2007","journal-title":"Brain."},{"key":"10.1007\/s13311-021-01122-6_bib127","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1126\/science.1178377","article-title":"Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation","volume":"326","author":"Zeqiraj","year":"2009","journal-title":"Science."},{"key":"10.1007\/s13311-021-01122-6_bib128","doi-asserted-by":"crossref","unstructured":"Parker WE, Orlova KA, Parker WH, et al. Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder. Sci Transl Med. 2013;5:182ra53.","DOI":"10.1126\/scitranslmed.3005271"},{"key":"10.1007\/s13311-021-01122-6_bib129","doi-asserted-by":"crossref","unstructured":"Ye Z, Chatterton Z, Pflueger J, et al. Cerebrospinal fluid liquid biopsy for detecting somatic mosaicism in brain. Brain Commun. 2021;3:fcaa235.","DOI":"10.1093\/braincomms\/fcaa235"},{"key":"10.1007\/s13311-021-01122-6_bib130","doi-asserted-by":"crossref","unstructured":"Kim S, Baldassari S, Sim NS, et al. Detection of Brain Somatic Mutations in Cerebrospinal Fluid from Refractory Epilepsy Patients. Ann Neurol. 2021.","DOI":"10.1002\/ana.26080"},{"key":"10.1007\/s13311-021-01122-6_bib131","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1177\/0883073817696814","article-title":"Targeting the Mammalian Target of Rapamycin for Epileptic Encephalopathies and Malformations of Cortical Development","volume":"33","author":"Jeong","year":"2018","journal-title":"J Child Neurol."},{"key":"10.1007\/s13311-021-01122-6_bib132","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1586\/ern.13.49","article-title":"mTOR inhibitors as a new therapeutic option for epilepsy","volume":"13","author":"Curatolo","year":"2013","journal-title":"Expert Rev Neurother."}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01122-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-021-01122-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923007559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923007559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01122-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:42:47Z","timestamp":1761806567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923007559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":132,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S1878747923007559"],"URL":"https:\/\/doi.org\/10.1007\/s13311-021-01122-6","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision Therapy for Epilepsy Related to Brain Malformations","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-021-01122-6","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}